- SynonymIGFBP4,IBP-4
- SourceHuman IGFBP-4, His Tag (IG4-H52E4) is expressed from human 293 cells (HEK293). It contains AA Asp 22 - Glu 258 (Accession # P22692-1).Predicted N-terminus: Asp 22Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.9 kDa. The protein migrates as 33-37 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human IGFBP-4, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human IGFBP-4, His Tag (Cat. No. IG4-H52E4) at 2 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag (Cat. No. IG1-H4269) with a linear range of 4-31 ng/mL (QC tested).
- BackgroundInsulin-like growth factor-binding protein 4 (IGFBP-4) is also known as IGF-binding protein 4, which contains an IGFBP domain and a thyroglobulin type-I domain. IGFBP-4 binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. IGFBP-4 is a unique protein and it consistently inhibits several cancer cells in vivo and in vitro. Its inhibitory action has been shown in vivo in prostate and colon. IGFBP-4 is secreted by all colon cancer cells.
- References
- (1)Tagliabracci V.S., et al., 2015, Cell 161:1619-1632.
- (2)Culouscou J.M., et al.,1991, Cancer Res. 51:2813-2819.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
